EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY

gan Madhukar, Neel, Prabhu, Varun Vijay, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Tarapore, Rohinton, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Elemento, Olivier, Free, R Benjamin, Sibley, David, Allen, Joshua E
Cyhoeddwyd yn Neuro Oncol (2017)

DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

gan Vijay Prabhu, Varun, Madhukar, Neel, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Tarapore, Rohinton, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Elemento, Olivier, Free, R Benjamin, Sibley, David, Allen, Joshua
Cyhoeddwyd yn Neuro Oncol (2018)

DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY

gan Prabhu, Varun, Cuoco, Caroline, Jung, Jinkyu, Rahman Kawakibi, Abed, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Charter, Neil, Rucker, Joseph, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Gilbert, Mark, Benjamin Free, R, Sibley, David, Allen, Joshua
Cyhoeddwyd yn Neuro Oncol (2019)

DDRE-33. MOLECULAR DIFFERENTIATION OF IMIPRIDONES ONC201 AND ONC206

gan Prabhu, Varun, Cuoco, Caroline, Jung, Jinkyu, Morrow, Sara, Kawakibi, Abed Rahman, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Charter, Neil, Rucker, Joseph, Doranz, Benjamin, Basken, Joel, Stogniew, Martin, Gilbert, Mark, Free, R, Sibley, David, Allen, Joshua
Cyhoeddwyd yn Neuro Oncol (2020)

EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY

gan Benjamin Free, R, Cuoco, Caroline, Prabhu, Varun, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Robert Lane, J, Sibley, David, Allen, Joshua
Cyhoeddwyd yn Neuro Oncol (2019)

MrgX2 is a promiscuous receptor for basic peptides causing mast cell pseudo‐allergic and anaphylactoid reactions

gan Grimes, Jak, Desai, Sapna, Charter, Neil W., Lodge, James, Moita Santos, Rita, Isidro‐Llobet, Albert, Mason, Andrew M., Wu, Zining, Wolfe, Lawrence A., Anantharaman, Lakshmi, Green, Andrew, Bridges, Angela M., Dalmas Wilk, Deidre A., Brown, Andrew J.
Cyhoeddwyd yn Pharmacol Res Perspect (2019)

Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia

gan Nii, Takenobu, Prabhu, Varun V., Ruvolo, Vivian, Madhukar, Neel, Zhao, Ran, Mu, Hong, Heese, Lauren, Nishida, Yuki, Kojima, Kensuke, Garnett, Mathew J., McDermott, Ultan, Benes, Cyril H., Charter, Neil, Deacon, Sean, Elemento, Olivier, Allen, Joshua E., Oster, Wolfgang, Stogniew, Martin, Ishizawa, Jo, Andreeff, Michael
Cyhoeddwyd yn Leukemia (2019)

EXTH-17. SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONISM BY IMIPRIDONE ONC206 IS EFFECTIVE IN TUMORS WITH DOPAMINE RECEPTOR DYSREGULATION

gan Prabhu, Varun Vijay, Madhukar, Neel, Tarapore, Rohinton, Garnett, Mathew, McDermott, Ultan, Benes, Cyril, Anantharaman, Lakshmi, Charter, Neil, Deacon, Sean, VanEngelenburg, Alexander, Rucker, Joseph, Doranz, Benjamin, Rusert, Jessica, Wechsler-Reya, Robert, Elemento, Olivier, Stogniew, Martin, Oster, Wolfgang, DeMorrow, Sharon, Free, R Benjamin, Sibley, David, Allen, Joshua
Cyhoeddwyd yn Neuro Oncol (2018)

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

gan Prabhu, Varun V., Madhukar, Neel S., Gilvary, Coryandar, Kline, C. Leah B., Oster, Sophie, El-Deiry, Wafik S., Elemento, Olivier, Doherty, Faye, VanEngelenburg, Alexander, Durrant, Jessica, Tarapore, Rohinton S., Deacon, Sean, Charter, Neil, Jung, Jinkyu, Park, Deric M., Gilbert, Mark R., Rusert, Jessica, Wechsler-Reya, Robert, Arrillaga-Romany, Isabel, Batchelor, Tracy T., Wen, Patrick Y., Oster, Wolfgang, Allen, Joshua E.
Cyhoeddwyd yn Clin Cancer Res (2018)